Cash/Burn From SEC Filing For Period: 

Q3 '19

KURA

Kura Oncology

We are a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our pipeline consists of small-molecule product candidates that target cancer signaling pathways, and we intend to pair them with molecular or cellular diagnostics to identify those patients most likely to respond to treatment.

Cash

$250.1M

Burn Rate

$16.4M

Amp Analysis

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

Tipifarnib

HRAS Mutant Head and Neck Cancer

Phase 3

Tipifarnib

Peripheral T-Cell Lymphoma (PTCL)

Phase 2

Q1 '19 - ASH 2019

Tipifarnib

Chronic Myelomonocytic Leukemia

Phase 2

1H 2020

Tipifarnib

Squamous Cell Carcinomas

Phase 2

2020

KO-947

Solid tumors

Phase 1

Late-2019 / early 2020

Tipifarnib

Pancreatic Cancer

Phase 1

2020

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

PROUDLY CREATED WITH WIX.COM

  • Twitter Social Icon
  • LinkedIn Social Icon